EHA 2017

Two is better than one: drug synergy in relapsed/refractory NHL 5:27
Two is better than one: drug synergy in relapsed/refractory NHL
Paul A. Hamlin
Key topics on AML at EHA 2017 2:34
Key topics on AML at EHA 2017
Oliver Ottmann
T-cell therapy: successes and unmet needs 0:52
T-cell therapy: successes and unmet needs
David Maloney
The ideal sequence: treating patients with CLL 2:31
The ideal sequence: treating patients with CLL
Florence Cymbalista
What are the non-drug-related aspects of patient care? 2:00
What are the non-drug-related aspects of patient care?
Claire Harrison
The potential of momelotinib against myeloproliferative malignancies 2:19
The potential of momelotinib against myeloproliferative malignancies
Claire Harrison
A CRISPR approach to hematological research 6:07
A CRISPR approach to hematological research
Sven Lundberg
What is the focus of EHA? 4:34
What is the focus of EHA?
Shai Izraeli
Venetoclax and ibrutinib: the future for treating WM 2:04
Venetoclax and ibrutinib: the future for treating WM
Steven Treon
NEOD001 in amyloidosis 0:53
NEOD001 in amyloidosis
Morie Gertz
Can a epoetin biosimilar be used to treat chemotherapy-induced anemia? 4:16
Can a epoetin biosimilar be used to treat chemotherapy-induced anemia?
Paul Cornes • 22 Jun 2017
Novel agents for myeloma related bone disease 3:39
Novel agents for myeloma related bone disease
Evangelos Terpos • 22 Jun 2017
Is denosumab superior to zoledronic acid in the treatment of bone metastases in MM? 4:26
Is denosumab superior to zoledronic acid in the treatment of bone metastases in MM?
Evangelos Terpos • 22 Jun 2017
HARMONY: a collaboration between 51 partners 0:52
HARMONY: a collaboration between 51 partners
Lars Bullinger • 22 Jun 2017
A question of age: how should elderly DLBCL patients be treated? 4:56
A question of age: how should elderly DLBCL patients be treated?
Marek Trněný • 22 Jun 2017
Future challenges facing hematological malignancies 2:24
Future challenges facing hematological malignancies
Robin Foà • 22 Jun 2017
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals